drugset / Trial / NCT04210427

Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

NCT04210427

Phase 4 Completed 3 enrolled St. Louis University
NaSingle-groupOpen-labelTreatment

Summary

The investigators will recruit 15 patients with cystic fibrosis 18 years of age and older who present with constipation. The investigators will assess baseline motility symptoms with a survey. Patients will then ingest a SmartPill (trademark) to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.

Timeline

Start
2019-12-12
Primary completion
2023-06-06
Completion
2023-06-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject polyethylene glycol Other / unclassified 17 g Oral

Indications